Oncotarget:DEPDC1在鼻咽癌细胞周期进程和动力学中扮演的角色。

2017-07-27 fengxiangxin MedSci原创

含DEP结构域的蛋白质1 (DEPDC1) ,一种新发现的癌症和细胞周期相关基因,已被证实为膀胱癌治疗的新靶点。然而,DEPDC1在鼻咽癌中的相关功能和治疗潜力尚不清楚。研究者在前期研究中发现:DEPDC1在鼻咽癌组织中的表达,无论在mRNA还是蛋白质水平,都较正常或非肿瘤组织高。

含DEP结构域的蛋白质1 (DEPDC1) ,一种新发现的癌症和细胞周期相关基因,已被证实为膀胱癌治疗的新靶点。然而,DEPDC1在鼻咽癌中的相关功能和治疗潜力尚不清楚。研究者在前期研究中发现:DEPDC1在鼻咽癌组织中的表达,无论在mRNA还是蛋白质水平,都较正常或非肿瘤组织高。

在鼻咽癌的两种细胞系,CNE-1和HNE-1中,siRNA介导的DEPDC1耗竭导致了明显的增值抑制和细胞周期的延迟。间接免疫荧光实验分析显示,DEPDC1耗竭显著阻滞了有丝分裂并伴随著有丝分裂缺陷如多极纺锤体和多核细胞,紧跟著出现细胞凋亡性死亡。

值得注意的是,DEPDC1耗竭同时减弱了两种细胞(CNE-1和HNE-1)的迁移和侵袭能力。与其在NF-κB 通路中的调控作用一致,敲除DEPDC1引起A20的显著上调以及NF-κB通路下游多个与细胞增值和肿瘤发生靶基因(c-myc、bcl-2、CCND1、CCNB1和CCNB2 )以及转移靶基因(MMP2,MMP9,ICAM1,波形蛋白,Twist1)的表达下调。此外,体内研究表明,敲除裸鼠移植瘤模型的DEPDC1基因后,鼻咽癌肿瘤生长受到明显抑制。

总之,此研究表明DEPDC1是加速鼻咽癌细胞周期进程和动力学所必不可少的。强烈建议将DEPDC1作为鼻咽癌治疗的一个新靶点。

原始出处:

Feng, X., C. Zhang, L. Zhu, et al., DEPDC1 is required for cell cycle progression and motility in nasopharyngeal carcinoma. Oncotarget, 2017.

本文系梅斯医学(MEDSCI)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1981815, encodeId=0002198181541, content=<a href='/topic/show?id=42221393e86' target=_blank style='color:#2F92EE;'>#pDC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13937, encryptionId=42221393e86, topicName=pDC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Sep 24 00:27:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795402, encodeId=5b4a1e95402d5, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri May 11 10:27:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252308, encodeId=5b56125230813, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287505, encodeId=ccb4128e50513, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227108, encodeId=029122e1082a, content=学习了,加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Fri Jul 28 07:14:51 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-09-24 chenlianhui
  2. [GetPortalCommentsPageByObjectIdResponse(id=1981815, encodeId=0002198181541, content=<a href='/topic/show?id=42221393e86' target=_blank style='color:#2F92EE;'>#pDC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13937, encryptionId=42221393e86, topicName=pDC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Sep 24 00:27:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795402, encodeId=5b4a1e95402d5, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri May 11 10:27:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252308, encodeId=5b56125230813, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287505, encodeId=ccb4128e50513, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227108, encodeId=029122e1082a, content=学习了,加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Fri Jul 28 07:14:51 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2018-05-11 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1981815, encodeId=0002198181541, content=<a href='/topic/show?id=42221393e86' target=_blank style='color:#2F92EE;'>#pDC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13937, encryptionId=42221393e86, topicName=pDC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Sep 24 00:27:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795402, encodeId=5b4a1e95402d5, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri May 11 10:27:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252308, encodeId=5b56125230813, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287505, encodeId=ccb4128e50513, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227108, encodeId=029122e1082a, content=学习了,加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Fri Jul 28 07:14:51 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-07-29 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=1981815, encodeId=0002198181541, content=<a href='/topic/show?id=42221393e86' target=_blank style='color:#2F92EE;'>#pDC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13937, encryptionId=42221393e86, topicName=pDC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Sep 24 00:27:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795402, encodeId=5b4a1e95402d5, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri May 11 10:27:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252308, encodeId=5b56125230813, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287505, encodeId=ccb4128e50513, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227108, encodeId=029122e1082a, content=学习了,加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Fri Jul 28 07:14:51 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1981815, encodeId=0002198181541, content=<a href='/topic/show?id=42221393e86' target=_blank style='color:#2F92EE;'>#pDC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13937, encryptionId=42221393e86, topicName=pDC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Sun Sep 24 00:27:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795402, encodeId=5b4a1e95402d5, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri May 11 10:27:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252308, encodeId=5b56125230813, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287505, encodeId=ccb4128e50513, content=<a href='/topic/show?id=1c48e783278' target=_blank style='color:#2F92EE;'>#细胞周期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77832, encryptionId=1c48e783278, topicName=细胞周期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 29 08:27:00 CST 2017, time=2017-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=227108, encodeId=029122e1082a, content=学习了,加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/25/50686bfef7f9754dfa5d0ccec059c9de.jpg, createdBy=8d992083353, createdName=139****9672, createdTime=Fri Jul 28 07:14:51 CST 2017, time=2017-07-28, status=1, ipAttribution=)]
    2017-07-28 139****9672

    学习了,加油

    0

相关资讯

2016十大临床研究

开展临床研究可为指南的制定和政策制定者提供证据,更好地促进临床决策,促进医学发展,更好地为患者服务。随着我国的发展,越来越多的中国研究发表在国际顶级期刊,发出了中国声音。 在过去的2016年,在国际的舞台上,有哪些中国的重磅研究精彩亮相?让我们一同来回眸。 1、黄连素能治不孕症 临床中一直用来治疗痢疾和肠胃炎的黄连素,竟对改善女性生殖功能也“露上一手”。 黑龙江中医药大学附属第

JCO:你知道哪种化疗方案对局部晚期鼻咽癌患者更有效吗?

2016年12月,发表在《J Clin Oncol》的一项由法国、中国、瑞士等国科学家进行的网络Meta分析,考察了哪种化疗方案对局部晚期鼻咽癌患者最有效。目的:辅助化疗(AC)或诱导化疗(IC)治疗局部晚期鼻咽癌的作用存在争议。来自鼻咽癌数据库对化疗的Meta分析中的个体患者数据,用于比较全部可用的治疗。方法:考虑针对非转移性鼻咽癌患者进行放疗或无化疗的全部随机试验(RT)。共纳入20项试验和5

Int Forum Allergy Rhinol:在美国,慢性鼻窦炎症是鼻咽癌和鼻窦恶性肿瘤的预兆因子

有研究表明,慢性炎症状态与恶性肿瘤的发展相关。在亚洲一个基于群体的研究中,慢性鼻窦炎(CRS)和过敏性鼻炎(AR)与鼻咽癌(NPC)相关。但是,一个相似的NPC和副鼻窦恶性肿瘤(PSM)与炎症的关系在北美人口中并没有被研究。最近,有研究人员调查了CRS和AR对NPC和PSM风险的影响。研究人员将监督、流行病学和最终结果(SEER)医疗保险相关数据库作为年龄不小于65岁成人的案例-对照研究查询对象。

八成鼻咽癌患者伴有颈部肿块,淋巴结发炎须警惕

全球鼻咽癌患者约有80%都是来自中国。在鼻咽癌患者中,又有60%~80%的患者最初表现为颈部肿块。记者从3月18日举办的第八届全国鼻咽癌学术大会上获悉,目前国内鼻咽癌早期患者5年生存率达90%以上。放疗作为治疗鼻咽癌的最常用手段,其疗效和副作用之间权衡向来是医生和患者共同关注的焦点。在中国,鼻咽癌发病率由南到北逐渐降低,以广东省发病率最高,曾一度被叫做“广东瘤”。其原因很复杂,与多种因素有关,如人

Theranostics:厦门大学林忠宁课题组发表鼻咽癌分子标志的筛查和靶向研究进展

近日,国际生命及医学科学领域的权威学术期刊《Theranostics》杂志上在线发表了厦门大学公共卫生学院林忠宁教授团队题为《Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-

香港中文大学率先成功破解鼻咽癌全基因组图谱

香港中文大学(中大)7日公布,其医学院研究人员率先成功破解鼻咽癌全基因组图谱,这是在全球已公布的研究中,首个有系统地进行鼻咽癌全基因组测序分析的研究。